Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Expert Opin Drug Discov. 2016 Dec 20;12(2):225–235. doi: 10.1080/17460441.2017.1268596

Table 2.

Ongoing clinical trials of Bortezomib in Mantle Cell Lymphoma

Name of Study Status Condition Intervention
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma Active, Not recruiting Mantle Cell Lymphoma Bortezomib, Rituximab, Cyclophosphamide, Vincristine, Methotrexate, Cytarabine, Doxorubicin
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Active, Not recruiting Mantle Cell Lymphoma EPOCH, Rituximab, Bortezomib
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma Active, Not recruiting Mantle Cell Lymphoma Rituximab, Bortezomib, Lenalidomide
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma Recruiting Mantle Cell Lymphoma Ibrutinib, Bortezomib
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10–011) Recruiting Mantle Cell Lymphoma Cladribine, Rituximab, Bortezomib
Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma Not Yet Recruiting Mantle Cell Lymphoma Bortezomib, Cytarabine, Dexamethasone, Pegfilgrastim
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Active, Not recruiting Mantle Cell Lymphoma Bortezomib, Lenalidomide
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Active, Not recruiting Lymphoma, mantle cell lymphoma, indolent lymphoma, SLL Cladribine, Rituximab, Bortezomib
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Recruiting Recurrent and refractory B-cell non-Hodgkin Lymphoma, recurrent and refractory mantle cell lymphoma Alisertib, Rituximab, Bortezomib
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Active, Not recruiting Recurrent adult diffuse large cell lymphoma, recurrent mantle cell lymphoma Vorinostat, Bortezomib
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL Recruiting Mantle cell lymphoma Rituximab, high dose Ara-C, Dexamethasone, Bortezomib
*

Data obtained from clinicaltrials.gov